Volume 3, Issue 2
Editorialp. 97
Long-term follow-up of human papillomavirus vaccine efficacy
Author(s): Matti Lehtinen
Editorialp. 101
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Author(s): Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
News and Viewsp. 105
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Author(s): Isaac Bruce
Conference Reportp. 109
The next generation of trial design innovation: strategies, methods and logistical considerations for flexible trial designs
Author(s): Terry L Katz, Sandeep Menon
Research Updatep. 113
Helping each other regulate clinical trials: a network of vaccine regulators from developing countries
Author(s): Sergio A Nishioka, James Southern, Rolando Dominguez, Nora Dellepiane
Clinical Trail Prospectivep. 119
Can mouse models of cancer reliably improve clinical trial outcome?
Author(s): Grit S Herter-Sprie & Kwok-Kin Wong
Clinical Trail Prospectivep. 131
What should be the primary end point in irritable bowel syndrome?
Author(s): Allen W Mangel
Review: Clinical Trail Outcomesp. 137
Future perspectives on the pharmacological management of depression
Author(s): Sarah Yates, Eleanor Smith, Hamid A Alhaj, R Hamish McAllister-Williams
Review: Clinical Trail Outcomesp. 153
New developments in the diagnosis and treatment of axial spondyloarthritis
Author(s): Pedro Machado, Robert Landewe, Desiree van der Heijde
Review: Clinical Trail Outcomesp. 173
Mesenchymal stem cells in neurological diseases
Author(s): Ibrahim Kassis, Panayiota Petrou, Adi Vaknin-Dembinsky, Dimitrios Karussis
Review: Clinical Trail Outcomesp. 191
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Author(s): Stanislas Pol
Acknowledgementsp. 209
